OLMA News

Latest breaking news and updates for OLMA stock.

Track all markets on TradingView

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

(NASDAQ:OLMA) SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the ...

What are the financial terms of the Pfizer supply agreement and could it lead to dilution, milestone payments, or significant cash inflows for Olema? How does the palazestrant + atirmociclib combination compare to existing ER+/HER2‑ therapies and competing pipelines in terms of efficacy and market potential? What is the expected timeline for trial readout and how might it drive short‑term volatility in Olema's stock?
Clinical trial
4 days ago
Read more globenewswire

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, deve...

Will the earnings release trigger any changes in analyst coverage or target price revisions for Olema Oncology? What is the expected impact of the Q2 results on the company's long-term strategic plan and market positioning? How might the reported results influence the company's upcoming investor presentations or conference calls?
Earnings
26 days ago
Read more globenewswire